The Association Between Serum Pentraxin-3 Level at Admission and the Functional Outcome of Patients After Acute Ischemic Stroke: A Meta-Analysis.

IF 1.9 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Balkan Medical Journal Pub Date : 2025-05-05 DOI:10.4274/balkanmedj.galenos.2025.2025-1-36

Yanrong Zhu, Kui Fan, Xujuan Zhao, Kaiwen Hou

{"title":"The Association Between Serum Pentraxin-3 Level at Admission and the Functional Outcome of Patients After Acute Ischemic Stroke: A Meta-Analysis.","authors":"Yanrong Zhu, Kui Fan, Xujuan Zhao, Kaiwen Hou","doi":"10.4274/balkanmedj.galenos.2025.2025-1-36","DOIUrl":null,"url":null,"abstract":"Background: Acute ischemic stroke (AIS) remains a leading cause of disability worldwide, placing a significant burden on patients' quality of life and healthcare systems. Pentraxin-3 (PTX-3), an inflammatory biomarker, may be associated with AIS prognosis; however, existing evidence is inconclusive.Aims: To examine whether serum PTX-3 levels at admission are linked to the likelihood of poor functional outcomes in AIS patients.Study design: Systematic review and meta-analysis.Methods: A comprehensive search of PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases was conducted to identify studies evaluating PTX-3 levels in AIS patients. Eligible studies included those that measured PTX-3 within 48 h of admission and evaluated outcomes using the modified Rankin Scale, with scores > 2 defined as poor outcomes. A random-effects model was used to calculate pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs).Results: Ten cohort studies involving1202 AIS patients were included. Higher PTX-3 levels at admission were significantly associated with an increased risk of poor functional outcomes (OR, 2.06; 95% CI, 1.72-2.47; p < 0.001), with no significant heterogeneity (I² = 0%). Meta-regression showed that using higher PTX-3 cutoff values reported stronger associations (p < 0.05). Subgroup analyses confirmed consistent associations across study designs, patient characteristics, and timing of outcome assessment. The association was more pronounced in studies using a PTX-3 cutoff ≥ 3.3 ng/mL compared to those with a cutoff < 3.3 ng/mL.Conclusion: Elevated serum PTX-3 levels at admission may serve as a prognostic biomarker for poor functional outcomes in AIS. Differences in PTX-3 cutoff values and potential residual confounding should also be considered. Further multicenter studies involving diverse populations are necessary to confirm these results and establish PTX-3 as a reliable prognostic indicator in clinical practice.","PeriodicalId":8690,"journal":{"name":"Balkan Medical Journal","volume":"42 3","pages":"201-211"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060599/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Balkan Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4274/balkanmedj.galenos.2025.2025-1-36","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Acute ischemic stroke (AIS) remains a leading cause of disability worldwide, placing a significant burden on patients' quality of life and healthcare systems. Pentraxin-3 (PTX-3), an inflammatory biomarker, may be associated with AIS prognosis; however, existing evidence is inconclusive.

Aims: To examine whether serum PTX-3 levels at admission are linked to the likelihood of poor functional outcomes in AIS patients.

Study design: Systematic review and meta-analysis.

Methods: A comprehensive search of PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases was conducted to identify studies evaluating PTX-3 levels in AIS patients. Eligible studies included those that measured PTX-3 within 48 h of admission and evaluated outcomes using the modified Rankin Scale, with scores > 2 defined as poor outcomes. A random-effects model was used to calculate pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs).

Results: Ten cohort studies involving1202 AIS patients were included. Higher PTX-3 levels at admission were significantly associated with an increased risk of poor functional outcomes (OR, 2.06; 95% CI, 1.72-2.47; p < 0.001), with no significant heterogeneity (I² = 0%). Meta-regression showed that using higher PTX-3 cutoff values reported stronger associations (p < 0.05). Subgroup analyses confirmed consistent associations across study designs, patient characteristics, and timing of outcome assessment. The association was more pronounced in studies using a PTX-3 cutoff ≥ 3.3 ng/mL compared to those with a cutoff < 3.3 ng/mL.

Conclusion: Elevated serum PTX-3 levels at admission may serve as a prognostic biomarker for poor functional outcomes in AIS. Differences in PTX-3 cutoff values and potential residual confounding should also be considered. Further multicenter studies involving diverse populations are necessary to confirm these results and establish PTX-3 as a reliable prognostic indicator in clinical practice.

查看原文本刊更多论文

入院时血清戊曲辛-3水平与急性缺血性脑卒中患者功能结局之间的关系：一项荟萃分析

背景：急性缺血性卒中（AIS）仍然是世界范围内致残的主要原因，对患者的生活质量和医疗保健系统造成了重大负担。炎症生物标志物ptraxin -3 （PTX-3）可能与AIS预后相关；然而，现有的证据是不确定的。目的：研究入院时血清PTX-3水平是否与AIS患者功能预后不良的可能性有关。研究设计：系统评价和荟萃分析。方法：综合检索PubMed、Embase、Web of Science、中国知网（CNKI）和万方数据库，确定评估AIS患者PTX-3水平的研究。符合条件的研究包括在入院48小时内测量PTX-3，并使用改进的Rankin量表评估结果，得分bbb20定义为不良结果。采用随机效应模型计算合并优势比（or）和相应的95%置信区间（ci）。结果：纳入10项队列研究，涉及1202例AIS患者。入院时较高的PTX-3水平与功能不良结局风险增加显著相关(OR, 2.06；95% ci, 1.72-2.47；p < 0.001)，无显著异质性（I²= 0%）。meta回归显示，PTX-3截断值越高，相关性越强（p < 0.05）。亚组分析证实了研究设计、患者特征和结果评估时间之间的一致关联。在PTX-3临界值≥3.3 ng/mL的研究中，与临界值< 3.3 ng/mL的研究相比，这种关联更为明显。结论：入院时血清PTX-3水平升高可作为AIS患者不良功能结局的预后生物标志物。还应考虑PTX-3截止值的差异和潜在的残留混淆。需要进一步开展涉及不同人群的多中心研究来证实这些结果，并将PTX-3作为临床实践中可靠的预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Balkan Medical Journal MEDICINE, GENERAL & INTERNAL-

CiteScore

4.10

自引率

6.70%

发文量

审稿时长

6-12 weeks

期刊介绍： The Balkan Medical Journal (Balkan Med J) is a peer-reviewed open-access international journal that publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports and clinical images, invited reviews, editorials, letters, comments and letters to the Editor including reports on publication and research ethics. The journal is the official scientific publication of the Trakya University Faculty of Medicine, Edirne, Turkey and is printed six times a year, in January, March, May, July, September and November. The language of the journal is English. The journal is based on independent and unbiased double-blinded peer-reviewed principles. Only unpublished papers that are not under review for publication elsewhere can be submitted. Balkan Medical Journal does not accept multiple submission and duplicate submission even though the previous one was published in a different language. The authors are responsible for the scientific content of the material to be published. The Balkan Medical Journal reserves the right to request any research materials on which the paper is based. The Balkan Medical Journal encourages and enables academicians, researchers, specialists and primary care physicians of Balkan countries to publish their valuable research in all branches of medicine. The primary aim of the journal is to publish original articles with high scientific and ethical quality and serve as a good example of medical publications in the Balkans as well as in the World.